

Disclosure of Relevant Financial Relationships with Commercial Companies

The Hope Foundation endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the American Medical Association. The Hope Foundation requires that all presentations at CME activities be fair, balanced, free of commercial bias, and fully supported by scientific evidence.

Everyone who is in a position to control the content of a continuing medical education activity is required to disclose relevant relationships with commercial companies whose products or services are discussed in educational presentations. The ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Disclosure of a relationship is not intended to suggest bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

All potential conflicts of interest have been resolved prior to this program.

A. Financial Disclosures Related to CME Activities and Requirements:

<u>Planner/Faculty Member</u>	<u>Nature of Relationship</u>	<u>Company</u>
Alex Adjei	No Disclosures	
Syed Ahmad	Speaker's Bureau	AbbVie
Sanjay Aneja	Research Grant	National Science Foundation, AHRQ, American Cancer Society, RSNA
Bob Arnold	Other	UpToDate Editor
Banu Arun	No Disclosures	
Marie Bakitas	No Disclosures	
Reva Basho	Speaker's Bureau	Genentech
Julie Behm	No Disclosures	
Charles Blanke	No Disclosures	
Jacek Capala	No Disclosures	
Young Chae	Consultant	BMS, Biodesix
	Speaker's Bureau	BMS
	Research Grant	BMS, Biodesix
Morgan Cox	No Disclosures	
Roy Decker	Consultant	AstraZeneca, Merck, Regeneron, Cybrexa, Novocure, Sanofi
	Speaker's Bureau	AstraZeneca
	Research Grant	Merck
Don Dizon	No Disclosures	
Lee Ellis	No Disclosures	
Harry Erba	Consultant	Agios, Amgen, Astellas, Celgene, Daiichi Sankyo, Incyte, Jazz, MacroGenics, Novartis, Pfizer
	Speaker's Bureau	Agios, Celgene, Incyte, Jazz, Novartis
	Honorarium	Covance
	Other	Chair of AML Registry Steering Committee for Celgene
Steven Finkelstein	Consultant	Jellyfish Health, Bayer, Janssen, Pfizer, Blue Earth
	Speaker's Bureau	Bayer, Janssen, Pfizer, Astellas

Jonathan Friedberg	Other	Patent Royalties (spouse)
Shirish Gadgeel	Consultant Research Grant	Genentech/Roche, Takeda, AstraZeneca, Novocure, BI Merck
Clarisa Gracia	No Disclosures	
Kenneth Grossmann	Consultant	Array
Norah Lynn Henry	Research Grant	Pfizer, AbbVie, Innocrin Pharmaceuticals
Dawn Hershman	No Disclosures	
Johanna Horn	No Disclosures	
Melinda Irwin	No Disclosures	
Dejan Juric	Consultant Research Grant	Novartis, Genentech, EMD Serono, Eisai, Ipsen, Guardant, Petra, Syros Novartis, Genentech, Takeda, Amgen, Syros, EMD Serono, Placon
Karen Kelly	Advisory Board iDMC Speaker's Bureau Research Grant	AstraZeneca, Merck, Pfizer, Regeneron, AbbVie AstraZeneca Merck AbbVie, EMD Serono
Justin Kline	Consultant Speaker's Bureau Research Grant	Merck Kite/Gilead Merck
Elise Kohn	No Disclosures	
Robert Krouse	No Disclosures	
Rita Kukafka	No Disclosures	
Mark Lewis	No Disclosures	
Jun Mao	Research Grant	Tibet Cheezheng Tibetan Medicine Co., Ltd., Zhongke Health International LLC
David McConkey	Consultant Research Grant	Janssen, Rainier Pharmaceuticals AstraZeneca, Rainier Pharmaceuticals
Miriam Merad	No Disclosures	
Michael Milano	No Disclosures	
Monica Mita	No Disclosures	
Halle Moore	Research Grant	PUMA and AbbVie
Marian Neuhouser	No Disclosures	
Paul Okunieff	No Disclosures	
Olufunmilayo Olopade	Other	Co-Founder of CancerIQ, Inc. (own stocks); Tempus Scientific Advisory Board
Robert Orlowski	Advisory Board Research Grant	Takeda, Sanofi-Aventis, Celgene, Amgen BioTheryx

Mark O'Rourke	No Disclosures	
Sandip Patel	Consultant Research Grant	AstraZeneca, BMS, Eli Lilly, Illumina, Nektar, Novartis, Tempus BMS, Eli Lilly, Fate, Incyte, AZ/MedImmune, Merck, Pfizer, Genentech/Roche, Xcovery
Philip Philip	Speaker's Bureau Honorarium Advisory Board Research Grant	Celgene, Ipsen, Bayer, Merck Ipsen, Halozyme Merck Meck, Merck, Celgene
Elizabeth Platz	Consultant Research Grant Other	Kaiser-Permanente Northern California (external advisor) NIH and DOD funding for research Editor in Chief of AACR Journal Cancer Epidemiology, Biomarkers & Prevention
Lajos Pusztai	Honorarium Research Grant	Merck, AstraZeneca, Seattle Genetics, Novartis, Athenex Susan Komen Foundation, Breast Cancer Research Foundation, NCI
Scott Ramsey	Consultant Steering Committee Advisory Board Other	BMS, Genentech AstraZeneca Bayer Pharmacy and Therapeutics Committee for Premera Blue Cross and Regence Blue Shield
Karen Reckamp	Consultant DSMC Research Grant Other	AstraZeneca, BI, Exelixis, Guardant, Loxo, Precision Health, Takeda Genentech, Tesaro AbbVie, Acea, Adaptimmune, BI, BMS, Genentech, GSK, Guardant, Janssen, Loxo, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, Zeno Thoracic Committee Co-Chair for Via Oncology Pathway
Bodour Salhia	No Disclosures	
Justin Sanders	No Disclosures	
Grace Smith	No Disclosures	
Bonnie Spring	No Disclosures	
Hussein Tawbi	Consultant Research Grant	BMS, Novartis, Array, Merck, Genentech BMS, Merck, Genentech, GSK, Celgene
Ian Thompson	Consultant Honorarium Research Grant/PI	Profound Medical, Partners/Harvard University University of Miami Cancer Center MagForce
Michael Wagner	Research Grant	Athenex
Ralph Weichselbaum	No Disclosures	
Courtney Wille	No Disclosures	

Christopher Wolfgang	No Disclosures	
----------------------	----------------	--

B. Financial Disclosures Related to Scientific Activities of SWOG

The relevant policy and process for disclosure of financial conflict of interest within SWOG are governed by Group Policy #35, "Financial Conflict of Interest Policy" (<http://swog.org/Visitors/Download/Policies/Policy35.pdf>) which was established in accordance with (and is consistent with) the Public Health Service regulation entitled "Responsibility of Applicants for promoting Objectivity in Research for which PHS Funding is Sought and Responsible Prospective Contractors" (42 CFR Part 50, 45 CFR 94, final rule published 8/25/2011). Policy #35 is made available to the public via the publicly accessible portion of SWOG's website. Federal regulations require that SWOG management plans be made available within 5 business days upon written request.